Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2018
Reporting Period: Event date January 8, 2018
Business Context: The Company is an emerging growth company focused on developing therapeutic products. This filing reports a significant clinical milestone regarding its investigational drug MAT2203.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a specific corporate event.
Material Changes
Clinical Development Milestone:
- Event: The Phase 2a clinical study of orally-administered MAT2203 for chronic refractory mucocutaneous candidiasis achieved its statistical endpoint for success.
- Study Sponsor: National Institutes of Health (NIH).
- Key Data: A third patient enrolled in the study met the primary endpoint, achieving a clinical response of ≥50%.
- Patient Profile: The patient had long-standing azole-resistant mucocutaneous candidiasis.
- Safety Profile: MAT2203 was well tolerated; observed adverse events were mild in severity and unrelated to the study drug.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release confirming the positive data relayed by NIH investigators. The achievement of the statistical hurdle with the third positive response marks a successful conclusion to the primary endpoint of this specific Phase 2a study.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard nature of clinical development. The text notes that adverse events observed were mild and unrelated to the drug.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study parameters.
- Confirm the specific statistical methodology used by the NIH to define the "statistical endpoint for success."
- Review subsequent filings for details on the next phases of development for MAT2203.
- Check the Company's latest 10-K or 10-Q for current cash runway and funding status, as this 8-K contains no financial data.